Roche’s CNS Drug Pipeline Matures: More Investment, More Promise
This article was originally published in Pharmaceutical Approvals Monthly
Roche Holding AG has established itself as a leader in areas like oncology, infectious disease, liver disease and inflammatory disease. Now the company is eyeing the central nervous system as a new frontier for its R&D, stealthily building a considerable clinical-stage pipeline in the process.
You may also be interested in...
The decision on whether Avastin’s metastatic breast cancer indication should be retained may come down to three words – “magnitude of benefit.”
Using a biomarker and investigational diagnostic, Roche has initiated a Phase II clinical trial of an amyloid-beta peptide antibody, gantenerumab, in patients with only mild cognitive deficits.
Finding growth opportunities in an era of constrained spending and health care reform is not an easy task, but an increasing number of companies operating in the diagnostics space are taking aim at one underserved area they believe will be a big winner in the years ahead: Alzheimer’s disease. This is a field still in its infancy and the risk of failure remains high. But as research progresses, it’s becoming clear that advances in AD diagnostics could play a major role in reducing that risk.